Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Abstract

Initial therapy of metastatic breast cancer with paclitaxel plus bevacizumab prolongs progression-free survival, but not overall survival, as compared with paclitaxel alone. (ClinicalTrials.gov number, NCT00028990 [ClinicalTrials.gov].).